RESUMO
BACKGROUND CONTEXT: Subependymomas are rare, slow-growing, and usually noninvasive/nonaggressive World Health Organization Grade I tumors that tend to occur in the ventricles. Their most common site of occurrence is the fourth ventricle followed by the lateral ventricles. Spinal cord subependymomas typically manifest as cervical and cervicothoracic intramedullary or, rarely, extramedullary mass lesions. They often present clinically with pain and neurologic symptoms, including motor, sensory, urinary, and sexual dysfunction. Histologically, there are hypocellular areas with occasional clusters of cells and frequent microcystic changes, calcifications, and hemorrhage. Radiologically, subependymomas generally manifest as eccentric well circumscribed nodular lesions with mild-to-moderate enhancement. PURPOSE: To highlight an interesting and rare presentation for subependymoma of the spinal cord. STUDY DESIGN: This is a case report of a single patient in whom a subependymoma was resected from the cervical spinal cord with return to normal functioning. METHODS: Clinical examination, magetic resonance imaging evaluation, surgical resection, and histological analysis were performed for diagnosis and treatment of this patient. RESULTS: The patient experiencing myelopathy symptoms underwent a surgical resection of cervical spinal cord subependymoma that resulted in return to normal function. CONCLUSIONS: Subependymoma should be included in the differential diagnosis of atypical presentations for myelopathy, as discrete surgical resection can result in good outcome.
Assuntos
Glioma Subependimal/diagnóstico , Doenças Raras/diagnóstico , Neoplasias da Medula Espinal/diagnóstico , Adulto , Diagnóstico Diferencial , Humanos , Perna (Membro) , Imageamento por Ressonância Magnética , Masculino , Espasmo/diagnósticoRESUMO
BACKGROUND: Symptomatic intracerebral hemorrhage (sICH) is the most devastating complication of thrombolytic therapy for acute stroke. It is not clear whether patients with sICH continue to bleed after diagnosis, nor has the most appropriate treatment been determined. METHODS: We performed a retrospective analysis of our prospectively collected Get With the Guidelines-Stroke database between April 1, 2003, and December 31, 2007. Radiologic images and all procoagulant agents used were reviewed. Multivariable logistic regression was performed to identify factors associated with in-hospital mortality. RESULTS: Of 2362 patients with acute ischemic stroke during the study period, sICH occurred in 19 of the 311 patients (6.1%) who received intravenous tissue plasminogen activator and 2 of the 72 (2.8%) who received intra-arterial thrombolysis. In-hospital mortality was significantly higher in patients with sICH than in those without (15 of 20 [75.0]% vs 56 of 332 [16.9%], P < .001). Eleven of 20 patients (55.0%) received therapy for coagulopathy: 7 received fresh frozen plasma; 5, cryoprecipitate; 4, phytonadione (vitamin K(1)); 3, platelets; and 1, aminocaproic acid. Independent predictors of in-hospital mortality included sICH (odds ratio, 32.6; 95% confidence interval, 8.8-120.2), increasing National Institutes of Health Stroke Scale score (1.2; 1.1-1.2), older age (1.3; 1.0-1.7), and intra-arterial thrombolysis (2.9; 1.4-6.0). Treatment for coagulopathy was not associated with outcome. Continued bleeding (>33% increase in intracerebral hemorrhage volume) occurred in 4 of 10 patients with follow-up scans available (40.0%). CONCLUSIONS: In many patients with sICH after thrombolysis, coagulopathy goes untreated. Our finding of continued bleeding after diagnosis in 40.0% of patients suggests a powerful opportunity for intervention. A multicenter registry to analyze management of thrombolysis-associated intracerebral hemorrhage and outcomes is warranted.
Assuntos
Antifibrinolíticos/uso terapêutico , Hemorragia Cerebral/induzido quimicamente , Hemorragia Cerebral/diagnóstico , Terapia Trombolítica/efeitos adversos , Ativador de Plasminogênio Tecidual/efeitos adversos , Idoso , Idoso de 80 Anos ou mais , Hemorragia Cerebral/metabolismo , Hemorragia Cerebral/terapia , Feminino , Fibrinogênio/metabolismo , Mortalidade Hospitalar , Humanos , Modelos Logísticos , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Estudos Retrospectivos , Acidente Vascular Cerebral/tratamento farmacológico , Resultado do TratamentoRESUMO
Quinine is often used as a treatment for benign nocturnal cramps. The use of Quinine remains controversial with conflicting studies regarding its efficacy. Quinine has a side effect profile that cannot be ignored. Cinchonism, or quinine toxicity, includes nausea, vomiting, and tinnitus. Many other side effects have been reported in the literature. A case report demonstrating the side effects of quinine is presented. We briefly review the literature on quinine and alternative medications.
Assuntos
Quinina/efeitos adversos , Transtornos da Transição Sono-Vigília/tratamento farmacológico , Comorbidade , Humanos , Masculino , Pessoa de Meia-Idade , Medicamentos sem Prescrição , Fitoterapia , Polimedicação , Quinina/uso terapêutico , Fatores de Tempo , Resultado do TratamentoRESUMO
Osteoporotic vertebral compression fractures result in an enormous medical, social and economic burden to society. Here, we review osteoporotic vertebral compression fractures, focusing on both their diagnosis and the treatment options, particularly vertebral augmentation.
Assuntos
Cimentos Ósseos/uso terapêutico , Fraturas por Compressão/terapia , Fraturas Espontâneas/terapia , Cifose/terapia , Osteoporose/complicações , Polimetil Metacrilato/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Fenômenos Biomecânicos , Conservadores da Densidade Óssea/uso terapêutico , Progressão da Doença , Feminino , Fixação Interna de Fraturas/economia , Fixação Interna de Fraturas/métodos , Fraturas por Compressão/diagnóstico , Fraturas por Compressão/economia , Fraturas Espontâneas/diagnóstico , Fraturas Espontâneas/economia , Humanos , Cifose/diagnóstico , Cifose/economia , Masculino , Pessoa de Meia-Idade , Procedimentos Ortopédicos/economia , Procedimentos Ortopédicos/métodos , Osteoporose/tratamento farmacológico , Resultado do TratamentoRESUMO
Over the past 15 years, endosaccular platinum coil therapy for intracranial aneurysms has evolved from clinical pilot studies of investigational devices to common clinical practice. The mechanism by which these coils reduce the risk of aneurysm rupture-the primary goal of intracranial aneurysm treatment-is the focus of this review. Both histological mechanisms of scar formation and hemodynamic mechanisms of flow diversion may be involved. We will first review aneurysm epidemiology to provide the context and rationale for therapy for patients harboring intracranial aneurysms. Next, we will review the data for and theories of the pathophysiology of aneurysm formation, growth, and rupture, particularly as they relate to endovascular coil therapy. Histological and hemodynamic studies of coiled aneurysms in animals and humans will be reviewed. Finally, we will discuss emerging coil-based therapies, such as bioactive polymer coatings for platinum coils and the adjunctive use of stents.